APOZEAL PHARMS
GenericsAPOZEAL PHARMS is a generic drug manufacturer focused on Oncology, Gastroenterology.
APOZEAL PHARMS's Key Drugs
APOZEAL PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
APOZEAL PHARMS's Recent FDA Approvals
New NDA/BLA approvals for APOZEAL PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
APOZEAL PHARMS's Therapeutic Areas
APOZEAL PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Gastroenterology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
APOZEAL PHARMS's Top Competitors
APOZEAL PHARMS's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
APOZEAL PHARMS Pipeline Snapshot
Active clinical trials for APOZEAL PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (2)
Company Info
- First Approval
- 2009-03-30
- Latest
- 2025-07-11
- Applications
- 11